These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35667200)

  • 1. Novel nanocarriers for silencing anti-phagocytosis CD47 marker in acute myeloid leukemia cells.
    Hassan EM; Zou S
    Colloids Surf B Biointerfaces; 2022 Sep; 217():112609. PubMed ID: 35667200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of Cancer Cells in Co-Culture: Role of Different Nanocarriers in Regulation of CD47 and Calreticulin-Induced Phagocytosis.
    Hassan EM; McWhirter S; Walker GC; Martinez-Rubi Y; Zou S
    ACS Appl Mater Interfaces; 2023 Jan; 15(3):3791-3803. PubMed ID: 36632842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
    Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
    Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
    Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
    J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
    J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-leukemia effect associated with down-regulated CD47 and up-regulated calreticulin by stimulated macrophages in co-culture.
    Hassan EM; Walker GC; Wang C; Zou S
    Cancer Immunol Immunother; 2021 Mar; 70(3):787-801. PubMed ID: 32995942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR3 agonism augments CD47 inhibition in acute myeloid leukemia.
    Ramsey HE; Gorska AE; Smith BN; Monteith AJ; Fuller L; Arrate MP; Savona MR
    Haematologica; 2024 Jul; 109(7):2111-2121. PubMed ID: 38152031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing graphene oxide nanocarriers for siRNA delivery in a 3D spheroid model of lung cancer.
    Grilli F; Hassan EM; Variola F; Zou S
    Biomater Sci; 2023 Sep; 11(19):6635-6649. PubMed ID: 37609774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.
    Theocharides AP; Jin L; Cheng PY; Prasolava TK; Malko AV; Ho JM; Poeppl AG; van Rooijen N; Minden MD; Danska JS; Dick JE; Wang JC
    J Exp Med; 2012 Sep; 209(10):1883-99. PubMed ID: 22945919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
    Majeti R; Chao MP; Alizadeh AA; Pang WW; Jaiswal S; Gibbs KD; van Rooijen N; Weissman IL
    Cell; 2009 Jul; 138(2):286-99. PubMed ID: 19632179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
    Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
    Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.
    Wang Y; Xu Z; Guo S; Zhang L; Sharma A; Robertson GP; Huang L
    Mol Ther; 2013 Oct; 21(10):1919-29. PubMed ID: 23774794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD47 protein expression in acute myeloid leukemia: A tissue microarray-based analysis.
    Galli S; Zlobec I; Schürch C; Perren A; Ochsenbein AF; Banz Y
    Leuk Res; 2015 Jul; 39(7):749-56. PubMed ID: 25943033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD47/SIRPα axis: bridging innate and adaptive immunity.
    van Duijn A; Van der Burg SH; Scheeren FA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
    Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
    Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibited CD47 gene affects the clearance of acute myelogenous leukemia stem cells.
    Song G; Yang L
    J Cell Biochem; 2019 Jun; 120(6):10303-10309. PubMed ID: 30565723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia.
    Melo Garcia L; Barabé F
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
    Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
    Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.